Lilly Undeterred By UK NICE Funding Blow For Second-Line Use Of Verzenios
UK HTA Body Has Issued A Preliminary Rejection Of Breast Cancer Drug For Routine Use
NICE says Verzenios is not cost-effective for previously treated breast cancer patients • Source: Shutterstock 
